Close

CareFusion Announces Preliminary Second Quarter Results

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Global Infection Control Market- $415 Billion on the Cards

As per the SNS insider, the global infection control...

AI in Healthcare Market to Reach $187.7 Billion by 2030

AI in Healthcare Market Revenue worth $187.7 Billion by...

Rise in Healthcare Grows Medical Device Technologies Market

The global medical device technologies market, which is valued...
CareFusion Corporation (NYSE: CFN) today announced preliminary second quarter results in advance of a presentation this afternoon by Chairman and CEO Kieran T. Gallahue at the annual J.P. Morgan Healthcare Conference.
The company said it expects revenue for its second fiscal quarter, ended Dec. 31, 2011, to be $910 million to $915 million and operating income to be $141 million to $146 million. Excluding nonrecurring items, adjusted operating income is expected to be $148 million to $153 million. CareFusion expects income from continuing operations per diluted share (EPS) for the quarter to be $0.39 to $0.43, or $0.41 to $0.45 on an adjusted basis.
CareFusion continues to expect full-year consolidated revenue for fiscal 2012 to grow 3 to 5 percent on a constant currency basis compared to fiscal 2011 revenue of $3.53 billion. The company lowered the bottom end of its full-year adjusted EPS guidance range by $0.05, to a new range of $1.75 to $1.90.
"Our Medical Systems segment continues to anchor us, with strong bookings in the quarter and good visibility through the second half of the year," said Gallahue. "While we continue to have scenarios that enable us to meet our original, full-year EPS commitments, results in our Procedural Solutions segment through Q2 are softer than we forecasted. Our core procedural products, including ChloraPrep® and non-dedicated infusion disposables, are performing well and growing faster than the market, just slightly below our expectations. In addition, our margins in the segment were negatively affected by pricing pressure on our less clinically differentiated products. During the quarter, we continued to make good progress with our simplification initiatives and remain committed to our long-term goals."

Latest stories

Related stories

Global Infection Control Market- $415 Billion on the Cards

As per the SNS insider, the global infection control...

AI in Healthcare Market to Reach $187.7 Billion by 2030

AI in Healthcare Market Revenue worth $187.7 Billion by...

Rise in Healthcare Grows Medical Device Technologies Market

The global medical device technologies market, which is valued...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back